Antibody-Drug Conjugates | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Optimal Implementation of Antibody-Drug Conjugates

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22) The Incidence and Management of Interstitial Lung Disease with ADCs (34:05) ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02) ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53) NCPD information and select publications